Skip to main content

Advertisement

Log in

N-Acetylation and hydroxylation polymorphisms in type II diabetics with microvascular disturbances

  • PHARMACOEPIDEMIOLOGY AND PRESCRIPTION
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

The N-acetylation and hydroxylation (CYP2D6) genetic polymorphisms were assessed in 43 healthy subjects and in 84 type II (non-insulin-dependent) diabetics. The proportions of slow and fast acetylators as well as poor and extensive metabolisers in a group of diabetics suffering from microvascular disturbances (nephropathy, retinopathy and neuropathy) were compared with the ocntrol group and with diabetics without such ocmplications. Sulphadimidine was used as a probe for polymorphic acetylation and debrisoqine for CYP2D6. Debrisoquine and its 4-OH metabolite were assayed by means of HPLC, and sulphadimidine using a modified Bratton-Marshall proceedure. The frequency of the slow phenotype (63%) was significantly higher in diabetics with microvascular disturbances than in patiens without diabetic complica tions (P < 0.005). In patients with type II diabetes (84), only the extensive phenotype of hydroxylation was observed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received: 18 March 1996 / Accepted in revised form: 11 July 1996

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gawrońska-Szklarz, B., Górnik, W., Pawlik, A. et al. N-Acetylation and hydroxylation polymorphisms in type II diabetics with microvascular disturbances. E J Clin Pharmacol 51, 431–435 (1997). https://doi.org/10.1007/s002280050226

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s002280050226

Navigation